Sequential administration of paricalcitol followed by IL-17 blockade for progressive refractory IgA nephropathy patients

Autor: Miguel G. Uriol-Rivera, Aina Obrador-Mulet, Maria Rosa Juliá, Vanessa Daza-Cajigal, Olga Delgado-Sanchez, Angel Garcia Alvarez, Ana Gomez-Lobon, Paula Carrillo-Garcia, Carlos Saus-Sarrias, Cristina Gómez-Cobo, Daniel Ramis-Cabrer, Joan Gasco Company, Javier Molina-Infante, The Balear IgA Research and Treatment Project
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Druh dokumentu: article
ISSN: 2045-2322
DOI: 10.1038/s41598-024-55425-7
Popis: Abstract There is no established treatment for progressive IgA nephropathy refractory to steroids and immunosuppressant drugs (r-IgAN). Interleukin 17 (IL-17) blockade has garnered interest in immune-mediated diseases involving the gut-kidney axis. However, single IL-17A inhibition induced paradoxical effects in patients with Crohn’s disease and some cases of de novo glomerulonephritis, possibly due to the complete Th1 cell response, along with the concomitant downregulation of regulatory T cells (Tregs). Seven r-IgAN patients were treated with at least six months of oral paricalcitol, followed by the addition of subcutaneous anti-IL-17A (secukinumab). After a mean follow-up of 28 months, proteinuria decreased by 71% (95% CI: 56–87), P
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje